ScholarWorks@Korea University: Park, Kyong Hwa

Detailed Information

Park, Kyong Hwa (박경화)

College of Medicine (Department of Medical Science)

Research Area

Tel 안6841
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast cancer:10||Chemotherapy:7||Breast neoplasms:6||lung cancer:6||Lung cancer:4||Metastatic breast cancer:4||RASSF1A:4||Gemcitabine:4||Korea:4||Metaanalysis:4||Docetaxel:4||Colorectal neoplasms:3||Adjuvant chemotherapy:3||Neutropenia:3||breast cancer:3||cellfree DNA:2||Survival:2||gastric cancer:2||KRAS:2||TAC chemotherapy:2||prognosis:2||FDG PET:2||prognostic model:2||Everolimus:2||EGFR mutation:2||cyclin B1:2||Oxaliplatin:2||overall survival:2||Lung adenocarcinoma:2||Pegylated GCSF:2||Breast cancer risk:2||Genomics:2||Nonsmallcell lung carcinoma:2||chemotherapy:2||Trastuzumab:2||POPULATIONS:2||docetaxel:2||Biomarkers:2||Vinorelbine:2||Sarcoma:2||Metastatic cancer:1||Neoplasm metastasis:1||streptavidin:1||Urothelial cancer:1||Carboplatin:1||Endoflife care:1||Cellfree nucleic acids quantification:1||Retrospective study:1||mTOR:1||MVAC protocol:1||Mammalian target of rapamycin inhibitor:1||Secondline chemotherapy:1||Prognostic factors:1||neoadjuvant chemotherapy:1||pathological complete response:1||Obesity:1||AntiEGFR:1||serum and tumor samples:1||CHINESE:1||elderly patients:1||Nonsmallcell lung cancer:1||Metastatic burden:1||Anthracyclines:1||Taxanes:1||FOLFIRI:1||Bevacizumab:1||Breast:1||Breast Cancer:1||Diagnosis:1||Tyrosine kinase inhibitors:1||refractory colon cancer:1||5FU:1||509 C/T polymorphism:1||Epirubicin:1||Anthracycline:1||IGFBP3:1||single nucleotide polymorphism (SNP):1||transcriptional activity:1||DHP107:1||HER2negative:1||Clustering:1||Molecular subtypes:1||immunotherapy:1||Highthroughput nucleotide sequencing:1||p53 protein:1||Cisplatinunfit:1||Mendelian randomization:1||Ovarian epithelial carcinoma:1||Clear cell adenocarcinoma:1||Clinical trial:1||Castrationresistant prostatic neoplasm:1||missense mutation:1||prognostic value:1||vinblastine:1||Caveolin 1:1||Febrile neutropenia:1||Ovarian neoplasms:1||Ovarian cancer:1||gold nanoparticles:1||p53 protein mutation:1||rayleigh scattering:1||cholangiocarcinoma:1||Cisplatin failure:1||Rab25:1||Vascular endothelial growth factor:1||CD8(+) T cell:1||Gene amplification:1||secondline chemotherapy:1||15Q25:1||ERCC1:1||276 C/T polymorphism:1||Korean population:1||Twin births:1||Janus kinase 3:1||Salvage treatment:1||mitomycin:1||vascular endothelial growth factor:1||Chemotherapy, second line:1||T helper 1:1||vincristine:1||IFN?:1||Gastric cancer:1||Menstruation:1||Palliative care:1||Oncology aesthetic:1||Gold nanoparticles (AuNPs):1||Plasmonic biosensors:1||Rosuvastatin:1||Principal component analysis:1||stop flow lithography:1||Prognosis:1||UVvis absorbance:1||Hairpin DNA:1||Irinotecan:1||Offlabel use:1||cellfree DNA concentration:1||Exemestane:1||methotrexate:1||Lymphoma:1||Clostridium difficile:1||localized surface plasmon resonance (LSPR):1||Prognostic marker:1||triplenegative breast cancer:1||Foxp3(+) Treg:1||Urothelial cell carcinoma:1||NSCLC:1||Health Partner Program:1||methylation:1||GENOMEWIDE ASSOCIATION:1||XUANWEI:1||POLYMORPHISMS:1||Stage:1||Overall survival:1||ACEI/ARB:1||capecitabine:1||Epidermal growth factor receptor mutation:1||Concomitant chemoradiation:1||Prognostic model:1||Adoptive T cell therapy:1||SNP:1||TNF?:1||Postmenopause:1||Advanced colorectal cancer:1||extracellular vesicle:1||tumor microenvironment:1||HSP90:1||Continuity of patient care:1||encoded hydrogel microparticle:1||azaMichael addition click reaction:1||Klenow fragment:1||Liquid biopsy:1||Advanced soft tissue sarcoma:1||IGF1R:1||aggressive fibromatosis:1||BRCA1 gene:1||Platinum resistant:1||Urothelial carcinoma:1||YKL40:1||Renal cell carcinoma:1||Tuberous sclerosis complex:1||carboplatin:1||IGFIR:1||Breast cancer antigen:1||Th1:1||Aged:1||longterm cancer survivors:1||health coaches:1||ADENOCARCINOMA:1||VARIANTS:1||COAL COMBUSTION EMISSIONS:1||SUSCEPTIBILITY LOCUS:1||CHINESE WOMEN:1||METAANALYSIS:1||Bone morphogenetic protein2:1||FOLFOX:1||Nasopharyngeal carcinoma:1||Sensitive:1||5Fluorouracil:1||firstline:1||metastatic breast cancer:1||Ovarian function:1||Letrozole:1||Minimized blood transfusion:1||urine:1||epitope mapping:1||Taxane acute pain syndrome:1||Doxorubicin:1||sequencing:1||mutations:1||probeset modification:1||Pathway analysis:1||Physician orders for lifesustaining treatment:1||Metabolic tumor volume:1||HER2Positive breast cancer:1||Lapatinib resistance:1||Apoptosis:1||colorectal cancer:1||genetic risk score:1||ErbB2:1||Treatment outcome:1||hot spot mutants:1||EGFR:1||endocytosis:1||bevacizumab:1||Th2:1||Gemcitabine and carboplatin:1||Protein expression:1||Drug therapy:1||Cisplatin:1||Squamous cell carcinoma of the head and neck:1||Polymorphism:1||VEGF:1||singlenucleotide polymorphism:1||haplotype:1||TGF?1:1||FSH:1||Patient blood management:1||Pain control:1||Candesartan:1||lapatinib resistance:1||COVID19:1||Advance directives:1||HER2:1||AuNPs:1||nonsmallcell lung carcinoma:1||Malignancy:1||response:1||Biliary tract cancer:1||Elderly:1||Receptor, epidermal growth factor:1||KRAS mutation:1||Solid cancer:1||Varicella zoster virus:1||KINASES:1||Reninangiotensin system:1||936 C/T polymorphism:1||Diffuse large B cell lymphoma:1||CD4 T cell:1||paclitaxel:1||cyclin A:1||Prognostic biomarker:1||Salvage therapy:1||liquid biopsy:1||Massage:1||Rayleigh scattering:1||Lapatinib:1||Total lesion glycolysis:1||DNA sensor:1||Capecitabine:1||molecular targeted therapy:1||nonsmallcell lung cancer:1||Ridaforolimus:1||Dalotuzumab:1||Secondline:1||early breast cancer:1||Pancreatic adenocarcinoma:1||SMOKERS:1||DISEASE:1||INDOOR AIRPOLLUTION:1||CANCER RISK:1||Haplotypes:1||Mammography:1||Granulysin:1||leucovorin:1||platelet count:1||Cancer vaccine:1||CT:1||Cancerrelated anemia:1||castrationresistant prostate cancer:1||immunity:1||Aromatherapy:1||Cardiomyopathy:1||ER (+) HER2 (+):1||Tuberculosis:1||CHA:1||Progressionfree survival:1||Phosphoproteomics:1||PAK2:1||Dovitinib:1||multiplex polymerase chain reaction:1||CXCR4:1||association study:1||genetics:1||telomere length:1||Peptide vaccine:1||Cancer stem cell:1||Spontaneous tumor:1||Neoadjuvant chemotherapy:1||PET computed tomographic:1||gefitinib:1||Colonic neoplasms:1||mTOR inhibitor:1||Serum and tumor samples:1||Weekly docetaxel:1||RISK:1||VTI1A:1||ERBB3 gene:1||Coarse Calcification:1||TGFbeta 1:1||Retrospective analysis:1||Esophageal squamous cell carcinoma:1||cyclindependent kinase 5 (CDK5):1||oral paclitaxel:1||E2:1||Tamoxifen:1||Receptors, estrogen:1||lymphocytes, tumorinfiltrating:1||

STATISTICS: Total View :6,953,437; Today View :19,505

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE